Intas Pharmaceuticals Overview
- Year Founded
-
1976
- Status
-
Private
- Employees
-
23,000
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
16
- Investments
-
4
Intas Pharmaceuticals General Information
Description
Manufacturer of pharmaceutical products intended to serve healthcare providers and patients. The company specializes in generic drugs, biosimilars, active pharmaceutical ingredients, injectable medicines, and oral solid dosage formulations, thereby enabling the treatment of various therapeutic areas, including oncology, cardiovascular, diabetology, gastroenterology, and neurology.
Contact Information
Website
www.intaspharma.comCorporate Office
- Corporate House, Near Sola Bridge
- S. G. Highway, Thaltej
- Ahmedabad, Gujarat 380054
- India
Corporate Office
- Corporate House, Near Sola Bridge
- S. G. Highway, Thaltej
- Ahmedabad, Gujarat 380054
- India
Intas Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Intas Pharmaceuticals Comparisons
Industry
Financing
Details
Intas Pharmaceuticals Competitors (50)
One of Intas Pharmaceuticals’s 50 competitors is MSN Laboratories, a Private Debt Financed company based in Hyderabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MSN Laboratories | Private Debt Financed | Hyderabad, India | ||||
| Serum Institute of India | Private Equity-Backed | Pune, India | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Novartis | Corporation | Basel, Switzerland |
Intas Pharmaceuticals Patents
Intas Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4813388-A1 | Combination of rupatadine and montelukast for use in the treatment of allergic rhinitis | Pending | 25-Mar-2025 | ||
| WO-2026202152-A1 | Combination of rupatadine and montelukast for use in the treatment of allergic rhinitis | Pending | 25-Mar-2025 | ||
| EP-4813387-A1 | Combination of rupatadine and montelukast for use in the treatment of seasonal allergic rhinitis | Pending | 25-Mar-2025 | ||
| WO-2026202147-A1 | Combination of rupatadine and montelukast for use in the treatment of seasonal allergic rhinitis | Pending | 25-Mar-2025 | ||
| WO-2026202644-A1 | Stable liquid formulation of hyaluronidase | Pending | 25-Mar-2025 | A61K47/26 |
Intas Pharmaceuticals Signals
Intas Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Intas Pharmaceuticals Investments (4)
Intas Pharmaceuticals’s most recent deal was a Buyout/LBO with Prothya Biosolutions. The deal was made on 20-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Prothya Biosolutions | 20-Oct-2025 | Buyout/LBO | BPO/Outsource Services | ||
| Udenyca | 11-Apr-2025 | Buyout/LBO | Buildings and Property | ||
| RPG Life Sciences (Biotech Unit) | 04-Oct-2016 | Buyout/LBO | Biotechnology | ||
| Biologics Process Development | 19-Jun-2008 | Buyout/LBO | Other Pharmaceuticals and Biotechnology |
Intas Pharmaceuticals Exits (1)
Intas Pharmaceuticals’s most recent exit was on 19-Jun-2008 from Biologics Process Development. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Biologics Process Development | 19-Jun-2008 | Completed |
|
Intas Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Prothya Biosolutions | Amsterdam, Netherlands | 2015 |
Intas Pharmaceuticals FAQs
-
When was Intas Pharmaceuticals founded?
Intas Pharmaceuticals was founded in 1976.
-
Where is Intas Pharmaceuticals headquartered?
Intas Pharmaceuticals is headquartered in Ahmedabad, India.
-
What is the size of Intas Pharmaceuticals?
Intas Pharmaceuticals has 23,000 total employees.
-
What industry is Intas Pharmaceuticals in?
Intas Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Intas Pharmaceuticals a private or public company?
Intas Pharmaceuticals is a Private company.
-
What is Intas Pharmaceuticals’s current revenue?
The current revenue for Intas Pharmaceuticals is .
-
How much funding has Intas Pharmaceuticals raised over time?
Intas Pharmaceuticals has raised $201M.
-
Who are Intas Pharmaceuticals’s investors?
Abu Dhabi Investment Authority and ChrysCapital have invested in Intas Pharmaceuticals.
-
Who are Intas Pharmaceuticals’s competitors?
MSN Laboratories, Serum Institute of India, Genentech, Pfizer (Vienna), and Novartis are some of the 50 competitors of Intas Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process